Author

Mohamed E. Abazeed

Primary ORCID profile (0000-0002-6614-4440 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Mohamed E. AbazeediD1 paper · Cleveland Clinic

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andrew DhawaniD· 1 shared Andriy MarusykiD· 1 shared Daniel Nichol· 1 shared Eric B. HauraiD· 1 shared Fumi Kinose· 1 shared Jacob G. ScottiD· 1 shared

Activity by Year

2017-2017 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew DhawanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer.

Andrew Dhawan, Daniel Nichol, Fumi Kinose, Mohamed E. Abazeed, Andriy Marusyk, Eric B. Haura, Jacob G. Scott

This study shows that resistance to ALK inhibitors in lung cancer is unstable and dynamic, with collateral sensitivity to other drugs offering new treatment options.

Scientific Reports · Apr 27, 2017Peer-reviewedCancer Biology